中国保健营养（中旬刊）
中國保健營養（中旬刊）
중국보건영양（중순간）
China Hwalth Care & nutrition
2013年
9期
766-766,767
,共2页
CYP2C19酶基因多态性%急性冠脉综合征%氯吡格雷抵抗
CYP2C19酶基因多態性%急性冠脈綜閤徵%氯吡格雷牴抗
CYP2C19매기인다태성%급성관맥종합정%록필격뢰저항
The CYP2C19 enzyme gene polymorphism%Acute coronary syndrome%Clopidogrel resistance
目的：探讨ACS患者PCI术后根据CYP2C19酶基因多态性给予氯吡格雷、阿司匹林抗血小板治疗后血小板聚集率变化及CR的发生情况。方法：ACS患者入院后服用阿司匹林、氯吡格雷，尽早行PCI治疗及CYP2C19酶基因多态性检测，根据CYP2C19酶基因多态性检测分EM组、IM组、PM组，所有入选患者分别于服用氯吡格雷前后测定血小板聚集率。结果：不同基因型之间服药后血小板聚集抑制率分别为17.5%、20.6%、21.9%（P＞0.05）差异无统计学意义，CR发生率分别为42.86%、18.97%、12.96%（P＜0.05）差异有统计学意义。结论：CYP2C19基因的多态性是氯吡格雷抵抗发生率高的危险因素，对高危患者进行CYP2C19基因的检测是必要的。
目的：探討ACS患者PCI術後根據CYP2C19酶基因多態性給予氯吡格雷、阿司匹林抗血小闆治療後血小闆聚集率變化及CR的髮生情況。方法：ACS患者入院後服用阿司匹林、氯吡格雷，儘早行PCI治療及CYP2C19酶基因多態性檢測，根據CYP2C19酶基因多態性檢測分EM組、IM組、PM組，所有入選患者分彆于服用氯吡格雷前後測定血小闆聚集率。結果：不同基因型之間服藥後血小闆聚集抑製率分彆為17.5%、20.6%、21.9%（P＞0.05）差異無統計學意義，CR髮生率分彆為42.86%、18.97%、12.96%（P＜0.05）差異有統計學意義。結論：CYP2C19基因的多態性是氯吡格雷牴抗髮生率高的危險因素，對高危患者進行CYP2C19基因的檢測是必要的。
목적：탐토ACS환자PCI술후근거CYP2C19매기인다태성급여록필격뢰、아사필림항혈소판치료후혈소판취집솔변화급CR적발생정황。방법：ACS환자입원후복용아사필림、록필격뢰，진조행PCI치료급CYP2C19매기인다태성검측，근거CYP2C19매기인다태성검측분EM조、IM조、PM조，소유입선환자분별우복용록필격뢰전후측정혈소판취집솔。결과：불동기인형지간복약후혈소판취집억제솔분별위17.5%、20.6%、21.9%（P＞0.05）차이무통계학의의，CR발생솔분별위42.86%、18.97%、12.96%（P＜0.05）차이유통계학의의。결론：CYP2C19기인적다태성시록필격뢰저항발생솔고적위험인소，대고위환자진행CYP2C19기인적검측시필요적。
Objective To investigate the ACS patients after PCI clopidogrel aspirin antiplatelet therapy, platelet aggregation rate changes and the occurrence of the CR, according to the patient's CYP2C19 enzyme gene polymorphism. Method ACS patients admit ed to hospital after taking aspirin, clopidogrel, as early as possible PCI treatment and the CYP2C19 enzyme gene polymorphism, EM group CYP2C19 gene polymorphism the IM group, the PM group, al enrol ed patients were taking clopidogrel before and after the determination of the rate of platelet aggregation. Result after taking platelet aggregation inhibition rate (DPAI) between the different genotypes were 17.5%, 20.6%and 21.9% (P> 0.05) difference was not statistical y significant, CR rates were 42.86%, 18.97%, 12.96% difference was statistical y significant (P <0.05). Conclusion CYP2C19 gene polymorphism is an risk factor of clopidogrel resistance, the high incidence of high-risk patients with CYP2C19 gene testing is necessary.
